Celcuity Wins FDA Approval for REVTORPYK in Breast Cancer
MINNEAPOLIS, Minn., July 14, 2026 Celcuity Inc. has achieved a major regulatory milestone after the U.S. Food and Drug...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
MINNEAPOLIS, Minn., July 14, 2026 Celcuity Inc. has achieved a major regulatory milestone after the U.S. Food and Drug...
SANTA CLARA, Calif., July 14, 2026 Autonomous Healthcare has achieved a landmark regulatory milestone after the U.S. Food and...
TELFORD, Pennsylvania, June 22, 2026 Draeger, Inc., the U.S. headquarters of global medical technology leader Dräger, has announced that...
Ingelheim, Germany – May 22, 2026 Boehringer Ingelheim announced that the European Medicines Agency’s Committee for Medicinal Products for...
MUMBAI, India, April 24, 2026 Cipla Limited continues to reinforce its position as a leading global pharmaceutical company, advancing...
Langhorne, Pennsylvania, USA, April 7, 2026 MHRA Acceptance Marks Key Regulatory Milestone In a significant advancement for rare disease...
LANGHORNE, Pa., March 30, 2026 Savara Inc. has achieved a major regulatory milestone as the European Medicines Agency (EMA)...
